证券代码：688687 证券简称：凯因科技 公告编号：2025-006 北京凯因科技股份有限公司 2024 年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股分配比例：每 10 股派发现金红利 3.00 元（含税），不进行公积 金转增股本，不送红股。 本次利润分配以实施权益分派股权登记日登记的公司总股本扣减回购 专用证券账户中股份数为基数，具体日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本扣减回购专用证券账户中 股份数发生变动的，按照每股分配比例不变的原则对分配总额进行调整，公司将 另行公告具体调整情况。 公司不触及《上海证券交易所科创板股票上市规则（2024 年 4 月修订）》 （以下简称《科创板股票上市规则》）第 12.9.1 条第一款第（八）项规定的可能 被实施其他风险警示的情形。 （一）利润分配方案的具体内容 经中汇会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日，公 司母公司报表中期末未分配利润为人民币 407,292,1 ...

Summary of the Gaming Industry Conference Call Industry Overview - The gaming industry is experiencing a new bull cycle with revenue and profit increases, supported by recent performance from companies like Perfect World, Gigabit, and Kain Technology in Q1 2025 [2][4] - The industry had previously faced valuation suppression due to regulatory issues, particularly the halt in game license approvals, but recent policy changes have alleviated these concerns [2][6] Key Company Performances - Perfect World's mobile game "Zhu Xian" generated 400 million yuan in its first month, declining to 200 million and then 100 million in subsequent months [2][7] - Gigabit's game "M72" achieved a revenue of 360 million yuan in Q1 2025 [2][7] - Kain Technology's "Dragon Valley" surpassed 200 million yuan in revenue, with the company reporting over 20% year-on-year growth [2][7] - Gigabit's net profit attributable to shareholders grew nearly 12%, with a nearly 40% increase in net profit excluding non-recurring items [2][7] Future Product Pipeline - Major gaming companies have a robust pipeline of upcoming products, including Perfect World's "Yihuan," Giant's "Supernatural Action," Kain's "Tomb Robbery Douluo," and Gigabit's "M88," which are expected to drive a fundamental turnaround in the gaming sector [2][8] AI Integration in Gaming - Significant advancements in AI integration within gaming have been noted, such as the closed beta testing of "Whispers from the Star" by Mihayou's AI company [2][9] - Kain Network and Giant Network are exploring AI commercial applications, including a native AI 3D boyfriend game and an evolving audio game generation model in collaboration with Alibaba Cloud [2][9] Market Sentiment and Recommendations - Anticipation of financial reports from major companies like Meta, Microsoft, and Tencent in May 2025 is expected to boost market risk appetite, making the gaming sector a recommended investment area [3][10] - Companies such as Tencent, Kain, Perfect World, Giant Network, and Gigabit are highlighted as key players to watch in this context [3][10] Regulatory Environment - The gaming industry has faced regulatory challenges, including two previous halts in game license approvals in 2018 and 2020, and a new regulation in December 2023 [5][6] - However, the resumption of license approvals and supportive policies from the National Press and Publication Administration and the State Council have improved market sentiment and valuations [6][6]

北京凯因科技股份有限公司 2024年度募集资金存放与使用情况 鉴证报告 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 www.zhcpa.cn Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 景 目 页 次 | 一、北京凯因科技股份有限公司 2024年度募集资金存放与使用情 | | --- | | 1-2 况鉴证报告 | 二、北京凯因科技股份有限公司关于 2024 年度募集资金存放与实 1-7 际使用情况的专项报告 三、事务所执业资质证明 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 www.zhcpa.cn Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 ...

国泰海通证券股份有限公司 关于北京凯因科技股份有限公司 2024 年度募集资金存放与使用情况的专项核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 北京凯因科技股份有限公司（以下简称"凯因科技"或"公司"）的持续督导机 构，根据《证券发行上市保荐业务管理办法》《上市公司监管指引第 2 号——上 市公司募集资金管理和使用的监管要求》《上海证券交易所科创板股票上市规则》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关规 定，对凯因科技 2024 年度募集资金存放与使用情况进行了审慎核查，具体情况 如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 （二）募集资金以前年度使用金额 截至 2024 年 12 月 31 日，公司累计使用募集资金 55,269.57 万元（包括置换 预先投入金额），本年度使用募集资金 4,566.38 万元，募集资金余额为 19,713.31 万元（含利息）。 （三）募集资金本年度使用金额及年末余额 2024 年度，公司使用募集资金 4,566.38 万元。截至 2024 年 12 月 31 日，公 司累计已使用募集资 ...

委托单位：北京凯因科技股份有限公司 审计单位：中汇会计师事务所（特殊普通合伙） 联系电话：010-67892271 关于北京凯因科技股份有限公司 2024年度非经营性资金占用及其他 关联资金往来情况的专项审核说明 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 www.zhcpa.cn Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road, Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 1、 专项审计报告 2、 附表 目 录 关于北京凯因科技股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 页 次 一、关于北京凯因科技股份有限公司 2024年度非经营性资金占用 1-2 及其他关联资金往来情况的专项审核说明 二、2024年度非经营性资金占用及其他关联资金往来情况汇总表 1 三、事务所执业资质证明 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 ...

国泰海通证券股份有限公司 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐人"）作为北 京凯因科技股份有限公司（以下简称"凯因科技"、"公司"或"发行人"）首次 公开发行股票并在科创板上市的保荐人，根据《证券发行上市保荐业务管理办法》 《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《上海证券交 易所科创板股票上市规则》等有关法律法规和规范性文件的要求，就凯因科技使 用暂时闲置募集资金进行现金管理的事项进行了审慎核查，并发表如下核查意 见: 一、募集资金基本情况 经中国证券监督管理委员会《关于同意北京凯因科技股份有限公司首次公开 发行股票注册的批复》（证监许可〔2021〕8 号）核准，公司首次公开发行股票 4,246 万股，每股发行价格为人民币 18.98 元，募集资金总额为人民币 80,589.08 万元，扣除各项发行费用后实际募集资金净额为人民币 72,586.61 万元。上述募 集资金到位情况已经中汇事务所（特殊普通合伙）验证，并由其出具中汇会验 [2021]0208 号《验资报告》。 上述募集资金已全部存放 ...

北京凯因科技股份有限公司 审计报告 2024 年度 中国杭州市钱江新城新业路 8号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel0571-88879999 Fax.0571-88879000 www.zhcpa.cn from 201 合由具有护 您可使用手机"扫一扫"或进入"注册 M | | 页 次 | | --- | --- | | 一、审计报告 | 1-6 | | 二、财务报表 | 1-12 | | (一) 合并资产负债表 | 1-2 | | (二) 合并利润表 | ങ | | (三) 合并现金流量表 | বা | | (四) 合并所有者权益变动表 | 5-6 | | (五) 母公司资产负债表 | 7-8 | | (六) 母公司利润表 | 9 | | (七) 母公司现金流量表 | 10 | | (八) 母公司所有者权益变动表 | 11-12 | 三、财务报表附注 13-108 四、事务所执业资质证明 中国杭州 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 231,594,549.40, representing an increase of 8.90% compared to CNY 212,673,809.18 in the same period last year[3] - Net profit attributable to shareholders was CNY 25,668,499.89, up 15.92% from CNY 22,144,168.59 year-on-year[3] - The basic earnings per share increased to CNY 0.15, reflecting a growth of 15.38% compared to CNY 0.13 in the same period last year[3] - The weighted average return on equity rose to 1.38%, an increase of 0.13 percentage points from the previous year[3] - The total comprehensive income for Q1 2025 was ¥25,457,646.89, compared to ¥24,435,627.84 in Q1 2024, indicating a year-over-year increase of 4.18%[20] Cash Flow - The net cash flow from operating activities improved significantly to CNY 5,867,946.35, compared to a negative cash flow of CNY 21,401,412.37 in the previous year[3] - Cash inflow from operating activities in Q1 2025 was ¥306,415,268.60, compared to ¥254,799,484.90 in Q1 2024, marking a rise of 20.25%[23] - The net cash flow from investing activities was -$6,546,054.13, an improvement from -$41,820,838.82 year-over-year[24] - Cash inflows from investing activities increased to $320,225,602.20, compared to $214,373,286.29 in the previous year[24] - The net cash flow from financing activities was -$4,962,686.72, a decline from a positive cash flow of $53,399,639.61 in the previous year[24] Expenses - Research and development expenses totaled CNY 26,277,546.81, a decrease of 9.58% from CNY 29,061,914.47, with R&D expenses accounting for 11.35% of revenue, down from 13.67%[4] - Total operating costs for Q1 2025 were ¥203,783,050.51, up from ¥191,738,956.41 in Q1 2024, reflecting a year-over-year increase of 6.18%[18] - The company reported a decrease in sales expenses to ¥114,742,965.35 in Q1 2025 from ¥103,972,619.47 in Q1 2024, showing improved cost management[18] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,520,928,379.89, a decrease of 3.62% from CNY 2,615,625,220.30 at the end of the previous year[4] - Total current assets decreased from CNY 1,860,100,437.22 as of December 31, 2024, to CNY 1,766,807,100.13 as of March 31, 2025, representing a decline of approximately 5.0%[12] - Total liabilities decreased to ¥612,302,223.30 in Q1 2025 from ¥735,327,270.60 in Q1 2024, a reduction of approximately 16.73%[15] - Total equity attributable to shareholders increased to ¥1,875,027,245.21 in Q1 2025 from ¥1,843,247,304.90 in Q1 2024, reflecting a growth of 1.73%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,805[8] - The largest shareholder, Beijing Song'an Investment Management Co., Ltd., held 22.46% of the shares, totaling 38,400,000 shares[8] Inventory and Fixed Assets - Inventory increased from CNY 144,238,608.29 to CNY 156,820,240.98, reflecting an increase of approximately 8.7%[13] - Fixed assets increased from CNY 245,864,224.69 to CNY 423,339,967.97, an increase of approximately 72.2%[13] - The company’s cash outflows for the acquisition of fixed assets and intangible assets were $12,771,656.33, significantly lower than $51,194,125.11 in the prior year[24]

Financial Performance - The company's operating revenue for 2024 was approximately ¥1.23 billion, a decrease of 12.87% compared to ¥1.41 billion in 2023[24]. - Net profit attributable to shareholders for 2024 was approximately ¥142.37 million, an increase of 22.18% from ¥116.52 million in 2023[24]. - The net profit after deducting non-recurring gains and losses for 2024 was approximately ¥136.98 million, up 11.75% from ¥122.58 million in 2023[24]. - The net cash flow from operating activities for 2024 was approximately ¥104.29 million, a decrease of 17.63% compared to ¥126.60 million in 2023[24]. - The total assets at the end of 2024 were approximately ¥2.62 billion, an increase of 6.84% from ¥2.45 billion at the end of 2023[24]. - The net assets attributable to shareholders at the end of 2024 were approximately ¥1.84 billion, reflecting a growth of 5.10% from ¥1.75 billion at the end of 2023[24]. - The company's operating revenue for 2024 was CNY 1,230.30 million, a decrease of 12.87% compared to 2023, primarily due to price reductions following the implementation of centralized procurement policies for key products[27]. - Basic and diluted earnings per share for 2024 were CNY 0.85, reflecting a year-on-year growth of 21.43%[27]. - The weighted average return on equity increased to 7.93% in 2024, up by 1.12 percentage points from 2023[27]. Dividend Distribution - The company plans to distribute a cash dividend of 3.00 CNY per 10 shares, totaling approximately 50.23 million CNY, which represents 35.28% of the net profit attributable to shareholders[6]. - The profit distribution plan has been approved by the board and will be submitted for shareholder approval at the 2024 annual general meeting[7]. Corporate Governance - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[9]. - There are no violations of decision-making procedures regarding external guarantees[9]. - The company has not disclosed any special arrangements for corporate governance[9]. - The board of directors, supervisory board, and senior management confirm the authenticity, accuracy, and completeness of the annual report[3]. - The company is committed to maintaining high standards of corporate governance, as evidenced by the stability in its board composition[167]. Research and Development - Research and development expenses accounted for 12.79% of operating revenue in 2024, an increase of 0.57 percentage points compared to the previous year[27]. - The company maintained a high R&D investment, totaling CNY 157.41 million, which accounted for 12.79% of operating revenue, and applied for 9 invention patents during the reporting period[40]. - The company has developed innovative drugs such as the pan-genotype oral drug and interferon α-2 injection, which have been industrialized successfully[44]. - The company has established a multi-target, multi-mechanism R&D pipeline in the field of viral hepatitis treatment, including projects KW-001, KW-027, and KW-040[68]. - The company has a total of 453 intellectual property rights, including 264 granted[65]. Market Strategy - The company follows a "sales-driven production" strategy, adjusting production plans based on market demand and sales forecasts[50]. - The company has established a comprehensive distribution system by collaborating with qualified pharmaceutical distributors across the country[51]. - The company is focused on expanding its product offerings in the pharmaceutical sector, particularly in the treatment of chronic hepatitis C[123]. - The company aims to accelerate the launch of new products and increase market share in 2025, focusing on innovative drug development and sales growth[152]. Regulatory Compliance - The company received an administrative regulatory measure decision from the China Securities Regulatory Commission on December 19, 2024[182]. - The company held meetings to address prior accounting errors and submitted a rectification report as required by the regulatory decision[183]. - The company disclosed corrected financial reports for the first three quarters of 2023 on December 20, 2024[183]. - The company has faced penalties from regulatory bodies in the past three years, necessitating corrective actions[182]. Employee and Management Information - The total compensation for the board members and senior management during the reporting period amounted to CNY 2,386.52 million[168]. - The company has a total of 600 employees, with 383 in the parent company and 217 in major subsidiaries[196]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 21.39 million RMB[179]. - The company has retained key personnel in core technology roles, ensuring continuity in its strategic direction and innovation efforts[169]. Future Outlook - The company provided an optimistic outlook for the next quarter, projecting revenue growth of 25% and aiming for $1.875 billion[170]. - The company plans to enhance its core competitiveness by focusing on innovative drug development for hepatitis B functional cure and immune disease prevention[132]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of $100 million allocated for potential deals[170].